IMMUNITYBIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
IMMUNITYBIO, INC. (IBRX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value of $58.50 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue · last filed 2026-08-04
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $58.50M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $40.32M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $17.00K.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $26.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value |
|---|---|
| 2026-06-30 | $58.50M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $40.32M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $17.00K 10-K · filed 2026-02-23 |
| 2025-09-30 | $26.00K 10-Q · filed 2025-11-05 |
| 2025-06-30 | $30.00K 10-Q · filed 2025-08-05 |
| 2025-03-31 | $87.00K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $90.00K 10-K · filed 2025-03-03 |
| 2024-09-30 | $1.94M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $10.79M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $4.82M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $4.12M 10-K · filed 2024-03-19 |
| 2023-09-30 | $105.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $640.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $234.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $2.74M 10-K · filed 2023-03-01 |
| 2022-09-30 | $2.65M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.48M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $3.39M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $3.98M 10-K · filed 2022-03-01 |
| 2021-09-30 | $9.82M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |